Immune-checkpoint inhibitors targeting PD-1 or PD-L1 have already substantially improved
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …

Immunotherapy has revolutionized cancer treatment and rejuvenated the field of tumor
immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and …

Immunotherapy with checkpoint blockade induces rapid and durable immune control of
cancer in some patients and has driven a monumental shift in cancer treatment. Neoantigen …

LAG-3, a type of immune checkpoint receptor protein belonging to the immunoglobulin
superfamily, is confirmed to be expressed on activated immune cells, mainly including …

Immune checkpoints are small molecules expressed by immune cells that play critical roles
in maintaining immune homeostasis. Targeting the immune checkpoints cytotoxic T …

Immune checkpoint inhibitors (ICIs) are a major class of immuno-oncology therapeutics that
have significantly improved the prognosis of various cancers, both in (neo) adjuvant and …

Cancer immunotherapy has become a new generation of anti-tumor treatment, but its
indications still focus on several types of tumors that are sensitive to the immune system …

PD-1 as an immune checkpoint molecule down-regulates T cell activity during immune
responses in order to prevent autoimmune tissue damage. In chronic infections or tumors …

The resurgence of cancer immunotherapy stems from an improved understanding of the
tumor microenvironment. The PD-1/PD-L1 axis is of particular interest, in light of promising …

Cancer immunotherapy has recently gained much attention in the search of cancer cure due
to its ability to “train” the immune system in seeking out and removing residual tumor cells …